Tenaya Therapeutics, Inc. Announces Annual Meeting of Stockholders

TL;DR

<b>Tenaya Therapeutics, Inc. is holding its virtual annual stockholder meeting on May 30, 2024, to elect directors and conduct other business.</b>

AI Summary

Tenaya Therapeutics, Inc. (TNYA) filed a Proxy Statement (DEF 14A) with the SEC on April 17, 2024. Tenaya Therapeutics, Inc. will hold its annual meeting of stockholders on May 30, 2024, at 8:00 a.m. Pacific Time. The meeting will be conducted virtually via a live audio webcast. Stockholders can attend, listen, submit questions, and vote online by visiting www.proxydocs.com/TNYA. The agenda includes the election of three Class III directors. The proxy statement details the business to be conducted at the meeting.

Why It Matters

For investors and stakeholders tracking Tenaya Therapeutics, Inc., this filing contains several important signals. This virtual format allows all stockholders to participate equally, regardless of location, ensuring broad engagement. The election of directors is a critical governance function that impacts the company's strategic direction and oversight.

Risk Assessment

Risk Level: — Tenaya Therapeutics, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational disclosures that would indicate significant risk.

Analyst Insight

Stockholders should review the proxy statement to understand the director nominees and any other proposals before voting.

Key Numbers

• 3 — Class III directors (To be elected at the annual meeting)
• 2027 — Director term end (Until the 2027 annual meeting of stockholders)

Key Players & Entities

• Tenaya Therapeutics, Inc. (company) — Registrant name
• Faraz Ali (person) — Chief Executive Officer
• May 30, 2024 (date) — Date of annual meeting
• 8:00 a.m. Pacific Time (time) — Time of annual meeting
• www.proxydocs.com/TNYA (url) — Link to attend virtual meeting

FAQ

Industry Context

Tenaya Therapeutics operates in the biotechnology sector, focusing on developing therapies for cardiovascular diseases.

Regulatory Implications

The filing is a standard proxy statement (DEF 14A) required by the SEC for public companies holding annual stockholder meetings.

What Investors Should Do

1. Review the list of director nominees and their qualifications.
2. Understand the procedures for virtual attendance and voting.
3. Consider any other proposals presented for stockholder vote.

Key Dates

• 2024-05-30: Annual Meeting of Stockholders — To elect directors and conduct other business.

Year-Over-Year Comparison

This filing is a DEF 14A, a routine proxy statement for an annual meeting, and does not represent a change from previous filings in terms of financial or operational updates.

Filing Documents

• d656970ddef14a.htm (DEF 14A) — 384KB
• g656970dsp043.jpg (GRAPHIC) — 243KB
• g656970dsp044.jpg (GRAPHIC) — 98KB
• g656970g06s06.jpg (GRAPHIC) — 23KB
• g656970g11l28.jpg (GRAPHIC) — 48KB
• 0001193125-24-099107.txt (&nbsp;) — 943KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 28 Processes and Procedures for Compensation Decisions 28 Summary Compensation Table for Fiscal 2023 28 Employment Arrangements 29 Executive Change in Control and Severance Plan 29 Equity Plans 31 Executive Incentive Compensation Plan 31 Clawback Policy 32 401(k) Plan 32 Outstanding Equity Awards at Fiscal 2023 Year-End 33 Equity Compensation Plan Information 34

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 35 RELATED PERSON TRANSACTIONS 38 Policies and Procedures for Related Person Transactions 39 OTHER MATTERS 40 Delinquent Section 16(a) Reports 40 Fiscal Year 2023 Annual Report 40 -i- Table of Contents TENAYA THERAPEUTICS, INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To be held at 8:00 a.m. Pacific Time on Thursday, May 30, 2024 The information provided in the question and answer format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read this entire proxy statement carefully. QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND OUR ANNUAL MEETING Why am I receiving these materials? This proxy statement and the form of proxy are furnished in connection with the solicitation of proxies by our board of directors for use at the 2024 annual meeting of stockholders of Tenaya Therapeutics, Inc., a Delaware corporation, and any postponements, adjournments or continuations thereof. The annual meeting will be held on Thursday, May 30, 2024, at 8:00 a.m. Pacific Time. The annual meeting will be conducted virtually via a live audio webcast. You will be able to attend the annual meeting virtually by visiting www.proxydocs.com/TNYA, where you will be able to listen to the meeting live, submit questions and vote online during the meeting by entering the control number on your proxy card. The Notice of Internet Availability of Proxy Materials, or Notice of Internet Availability, containing instructions on how to access this proxy statement, the accompanying notice of annual meeting and form of proxy, and our annual report, is first being sent or given on or about April 17, 2024, to all stockholders of record as of the close of business on April 1, 2024. The proxy materials and our annual report can be accessed as of April 17, 2024, by visiting www.proxydocs.com/TNYA. If you receive